Live tv
search
  1. You Are At:
  2. English News
  3. India
  4. Covaxin booster dose neutralises Omicron, as well as Delta variants, says Bharat Biotech

Covaxin booster dose neutralises Omicron, as well as Delta variants, says Bharat Biotech

Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.

Shashwat Bhandari Edited by: Shashwat Bhandari @ShashBhandari
New Delhi Updated on: January 12, 2022 18:26 IST
Representational image.
Image Source : FILE PHOTO

Representational image.

Highlights

  • Covaxin booster dose generated robust neutralizing antibody against both Omicron, Delta variants
  • 100% of test serum samples showed neutralization of Delta, more than 90% of serum samples in Omicron
  • Covaxin is a viable option in this continuously evolving pandemic

Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.

Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Wednesday announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants.

Earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa. The study will be published on the pre-print server, medRXiv, shortly.

Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay.

The neutralization activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with Covaxin showed neutralizing antibodies. All participants received an initial two-dose schedule of Covaxin at Day 0 and Day 28.

“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, Ph.D., Assistant Professor, Emory Vaccine Center and who led the laboratory analysis.

“Data from this preliminary analysis show individuals receiving a booster dose of COVAXIN®️ have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations.”

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We are in a continuous state of innovation and product development for Covaxin. The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covaxin as a universal vaccine for adults and children.”

“The global impact of Omicron shows us that the fight against COVID-19 continues, and we’re encouraged that these data demonstrate the value of Covaxin as a primary and booster vaccine,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc.

“These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations.”

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children alike.

Covaxin is a ready-to-use, liquid vaccine, stored at 2 - 8°C, with 12 months shelf life and multi-dose vial policy. The same doses of vaccine can also be used for two-dose primary immunization in adults and children and for booster dose vaccinations, making it truly a universal vaccine.

ALSO READCovid: Maharashtra, West Bengal, Delhi, Karnataka emerge as 'states of concern,' says Centre

ALSO READ | Fresh 1.94 lakh cases take active tally to 211-day high of 9,55,319 lakh

 

Latest India News